# MSB11022 in Healthy Subjects

> **NCT03014947** · PHASE1 · COMPLETED · sponsor: **Fresenius Kabi SwissBioSim GmbH** · enrollment: 237 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** MSB11022
- **DRUG:** US-licensed Humira
- **DRUG:** EU-approved Humira

## Key facts

- **NCT ID:** NCT03014947
- **Lead sponsor:** Fresenius Kabi SwissBioSim GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2019-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03014947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03014947, "MSB11022 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03014947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*